Special Educational Needs: support in England
An overview of the current system of support for children and young people with special educational needs, and pressure on the system. Updated with new 2024-25 SEND incidence and EHC plan data

This pack has been prepared ahead of the debate to be held in Westminster Hall on Thursday 21 June 2018 at 1.30pm on Myalgic Encephalomyelitis treatment and research. The subject for the debate has been selected by the Backbench Business Committee and the debate will be opened by Carol Monaghan MP.
Commons Library debate pack: Myalgic Encephalomyelitis treatment and research (373 KB , PDF)
A debate on Myalgic Encephalomyelitis: Treatment and Research will take place in Westminster Hall on 21 June 2018. The debate will be led by Carol Monaghan MP.
There has been recent debate on a number of issues relating to treatment and research for Myalgic Encephalomyelitis (ME). These have included calls for improved awareness of this condition and greater provision of services and specialist care. Following a recent review, clinical guidelines on the diagnosis and management of this condition are currently being updated.
Both the type and funding of research undertaken into this condition is also an issue that has been raised recently. Charities and campaigners report that funding is significantly less than for conditions with a similar prevalence and disease burden.[1]
[1] ME Association, Action for M.E., ME Trust and #ME action, Parliamentary briefing for Carol Monaghan MP’s debate on Myalgic Encephalomyelitis Treatment and research, 12 June 2018
Commons Library debate pack: Myalgic Encephalomyelitis treatment and research (373 KB , PDF)
An overview of the current system of support for children and young people with special educational needs, and pressure on the system. Updated with new 2024-25 SEND incidence and EHC plan data
The Rare Cancers Bill 2024-2025 had its second reading on Friday 14 March 2025. It was considered in Public Bill Committee on 2 July 2025 and report stage is scheduled for 11 July 2025. This is a private members' bill.
This briefing focuses on two disease-modifying dementia drugs that are currently being appraised by the National Institute for Health and Care Excellence (NICE): lecanemab and donanemab